Energy metabolism analysis reveals the mechanism of inhibition of breast cancer cell metastasis by PEG-modified graphene oxide nanosheets

Biomaterials

Volumn 35, Issue 37, 2014, Pages 9833-9843

  Zhou, Teng ^a,e   Zhang, Bo ^a   Wei, Peng ^a,e   Du, Yipeng ^a   Zhou, Hejiang ^a,e   Yu, Meifang ^a,e   Yan, Liang ^b,e   Zhang, Wendi ^c,e   Nie, Guangjun ^c   Chen, Chunying ^b,c   Tu, Yaping ^d   Wei, Taotao ^a  

^a INSTITUTE OF BIOPHYSICS   (China)

^b INSTITUTE OF HIGH ENERGY PHYSICS   (China)

^c NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Breast cancer cell; Cytoskeletal assembly; Metastasis; Mitochondrial oxidative phosphorylation; PEG modified graphene oxide

Indexed keywords

BIOCOMPATIBILITY; CELL CULTURE; GRAPHENE; MEDICAL NANOTECHNOLOGY; METABOLISM; MITOCHONDRIA; PATHOLOGY; PATIENT TREATMENT; PHOSPHORYLATION; PROTEINS;

BREAST CANCER CELLS; CYTOSKELETAL; GRAPHENE OXIDE NANOSHEETS; METASTASIS; METASTATIC DISEASE; MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION; PROTEIN EXPRESSIONS; STABLE-ISOTOPE LABELING;

DISEASES;

AMINO ACID; GRAPHENE OXIDE; MACROGOL; GRAPHITE; MACROGOL DERIVATIVE; OXIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ATOMIC FORCE MICROSCOPY; BIOCOMPATIBILITY; BREAST CANCER; BREAST METASTASIS; CANCER INHIBITION; CELL CULTURE; CELL ENERGY; CELL METABOLISM; CELL MIGRATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; CYTOSKELETON; ENDOCYTOSIS; ENERGY METABOLISM; GLYCOLYSIS; HUMAN; HUMAN CELL; ISOTOPE LABELING; METASTASIS; NANOMEDICINE; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; PROTEIN EXPRESSION; BREAST; BREAST TUMOR; CELL LINE; CELL MOTION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM METASTASIS; PATHOLOGY; TUMOR CELL LINE;

BREAST; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; ENERGY METABOLISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRAPHITE; HUMANS; NEOPLASM METASTASIS; OXIDES; POLYETHYLENE GLYCOLS;

EID: 84907260833     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.08.033     Document Type: Article

References (47)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
3. Chiang A.C., Massague J. Molecular basis of metastasis. New Engl J Med 2008, 359:2814-2823.
4. Park J.H., von Maltzahn G., Xu M.J., Fogal V., Kotamraju V.R., Ruoslahti E., et al. Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc Natl Acad Sci U S A 2010, 107:981-986.
5. Chow E.K., Ho D. Cancer nanomedicine: from drug delivery to imaging. Sci Transl Med 2013, 5:216rv4.
6. Farrell D., Alper J., Ptak K., Panaro N.J., Grodzinski P., Barker A.D. Recent advances from the National Cancer Institute alliance for nanotechnology in cancer. ACS Nano 2010, 4:589-594.
7. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. JClin Oncol 2005, 23:7794-7803.
8. Zamboni W.C., Ramalingam S., Friedland D.M., Edwards R.P., Stoller R.G., Strychor S., et al. Phase I and pharmacokinetic study of PEGylated liposomal CKD-602 in patients with advanced malignancies. Clin Cancer Res 2009, 15:1466-1472.
9. Barreto J.A., O'Malley W., Kubeil M., Graham B., Stephan H., Spiccia L. Nanomaterials: applications in cancer imaging and therapy. Adv Mater 2011, 23:H18-H40.
10. Geim A.K., Novoselov K.S. The rise of graphene. Nat Mater 2007, 6:183-191.
11. Geim A.K. Graphene: status and prospects. Science 2009, 324:1530-1534.
12. Zhu Y., Murali S., Cai W., Li X., Suk J.W., Potts J.R., et al. Graphene and graphene oxide: synthesis, properties, and applications. Adv Mater 2010, 22:3906-3924.
13. Wang Y., Li Z., Wang J., Li J., Lin Y. Graphene and graphene oxide: biofunctionalization and applications in biotechnology. Trends Biotechnol 2011, 29:205-212.
14. Yang K., Wan J., Zhang S., Zhang Y., Lee S.T., Liu Z. Invivo pharmacokinetics, long-term biodistribution, and toxicology of PEGylated graphene in mice. ACS Nano 2011, 5:516-522.
15. Miao W., Shim G., Lee S., Lee S., Choe Y.S., Oh Y.K. Safety and tumor tissue accumulation of PEGylated graphene oxide nanosheets for co-delivery of anticancer drug and photosensitizer. Biomaterials 2013, 34:3402-3410.
16. Yang K., Zhang S., Zhang G., Sun X., Lee S.T., Liu Z. Graphene in mice: ultrahigh invivo tumor uptake and efficient photothermal therapy. Nano Lett 2010, 10:3318-3323.
17. Wen H., Dong C., Dong H., Shen A., Xia W., Cai X., et al. Engineered redox-responsive PEG detachment mechanism in PEGylated nano-graphene oxide for intracellular drug delivery. Small 2012, 8:760-769.
18. Yin D., Li Y., Lin H., Guo B., Du Y., Li X., et al. Functional graphene oxide as a plasmid-based Stat3 siRNA carrier inhibits mouse malignant melanoma growth invivo. Nanotechnology 2013, 24:105102.
19. Feng L., Yang X., Shi X., Tan X., Peng R., Wang J., et al. Polyethylene glycol and polyethylenimine dual-functionalized nano-graphene oxide for photothermally enhanced gene delivery. Small 2013, 9:1989-1997.
20. Liu Z., Robinson J.T., Sun X., Dai H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. JAm Chem Soc 2008, 130:10876-10877.
21. Shi J., Wang L., Zhang J., Ma R., Gao J., Liu Y., et al. Atumor-targeting near-infrared laser-triggered drug delivery system based on GO@Ag nanoparticles for chemo-photothermal therapy and X-ray imaging. Biomaterials 2014, 35:5847-5861.
22. Arvizo R.R., Saha S., Wang E., Robertson J.D., Bhattacharya R., Mukherjee P. Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. Proc Natl Acad Sci U S A 2013, 110:6700-6705.
23. Zhou H., Zhang B., Zheng J., Yu M., Zhou T., Zhao K., et al. The inhibition of migration and invasion of cancer cells by graphene via the impairment of mitochondrial respiration. Biomaterials 2014, 35:1597-1607.
24. Yan L., Chang Y., Zhao L., Gu Z., Liu X., Tian G., et al. The use of polyethylenimine-modified graphene oxide as a nanocarrier for transferring hydrophobic nanocrystals into water to produce water-dispersible hybrids for use in drug delivery. Carbon 2013, 57:120-129.
25. Zhou H., Zhao K., Li W., Yang N., Liu Y., Chen C., et al. The interactions between pristine graphene and macrophages and the production of cytokines/chemokines via TLR- and NF-κB-related signaling pathways. Biomaterials 2012, 33:6933-6942.
26. Boire A., Covic L., Agarwal A., Jacques S., Sherifl S., Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005, 120:303-313.
27. Xie Y., Wolff D.W., Wei T., Wang B., Deng C., Kirui J.K., et al. Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4. Cancer Res 2009, 69:5743-5751.
28. Delahunty C., Yates J.R. Protein identification using 2D-LC-MS/MS. Methods 2005, 35:248-255.
29. Harsha H.C., Molina H., Pandey A. Quantitative proteomics using stable isotope labeling with amino acids in cell culture. Nat Protoc 2008, 3:505-516.
30. Machesky L.M. Lamellipodia and filopodia in metastasis and invasion. FEBS Lett 2008, 582:2102-2111.
31. Koestler S.A., Rottner K., Lai F., Block J., Vinzenz M., Small J.V. F- and G-actin concentrations in lamellipodia of moving cells. PLoS One 2009, 4:e4810.
32. Pollard T.D., Cooper J.A. Actin, a central player in cell shape and movement. Science 2009, 326:1208-1212.
33. Chen Z., Lu W., Garcia-Prieto C., Huang P. The Warburg effect and its cancer therapeutic implications. JBioenerg Biomembr 2007, 39:267-274.
34. Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet 2000, 25:25-29.
35. Harris M.A., Clark J.I., Ireland A., Lomax J., Ashburner M., Collins R., et al. The gene ontology (GO) project in 2006. Nucleic Acids Res 2006, 34:D322-D326.
36. Kanehisa M., Goto S., Kawashima S., Okuno Y., Hattori M. The KEGG resource for deciphering the genome. Nucleic Acids Res 2004, 32:D277-D280.
37. Yi M., Horton J.D., Cohen J.C., Hobbs H.H., Stephens R.M. WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data. BMC Bioinform 2006, 7:30.
38. Zhao J., Zhang J., Yu M., Xie Y., Huang Y., Wolff D.W., et al. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene 2013, 32:4814-4824.
39. Yamaguchi H., Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta 2007, 1773:642-652.
40. Pollard T.D., Borisy G.G. Cellular motility driven by assembly and disassembly of actin filaments. Cell 2003, 112:453-465.
41. Kovar D.R., Harris E.S., Mahaffy R., Higgs H.N., Pollard T.D. Control of the assembly of ATP- and ADP-actin by formins and profilin. Cell 2006, 124:423-435.
42. Le Clainche C., Carlier M.F. Regulation of actin assembly associated with protrusion and adhesion in cell migration. Physiol Rev 2008, 88:489-513.
43. Scarpulla R.C. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta 2011, 1813:1269-1278.
44. Austin S., St-Pierre J. PGC1α and mitochondrial metabolism-emerging concepts and relevance in ageing and neurodegenerative disorders. JCell Sci 2012, 125:4963-4971.
45. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010, 9:447-464.
46. Wang L., Liu Y., Li W., Jiang X., Ji Y., Wu X., et al. Selective targeting of gold nanorods at the mitochondria of cancer cells: implications for cancer therapy. Nano Lett 2011, 11:772-780.
47. Minn A.J. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. JClin Invest 2005, 115:44-55.